2
icotec AG Received FDA Clearance to Market BlackArmor® Carbon/PEEK Interbody Cages
mehr
Storys zum Thema Medicale
Grünenthal Initiates Pivotal Phase III Trials in Complex Regional Pain Syndrome
Aachen, Germany (ots) - Grünenthal announced today that first patients have been enrolled in two trials of the company's pivotal phase III program investigating neridronate for the treatment of Complex Regional Pain Syndrome (CRPS). These two trials, KF7013-02 and KF7013-04, are investigating the efficacy and safety of neridronate in 360 patients with CRPS. ...
mehrJanssen to Showcase New Data Across Broad Rheumatology Portfolio and Immunology Pipeline at EULAR 2018
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE ONLY The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that ten company-sponsored abstracts will be presented at the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam, Netherlands being held on 13-16 June. Data from the ...
mehrNew UCB Data Presented at the Annual European Congress of Rheumatology (EULAR 2018) Serves Key Patient Populations Including Ankylosing Spondylitis, Psoriatic Arthritis, and Women with Chronic Inflammatory Diseases
Brussels (ots/PRNewswire) - - Late-breaking oral presentation on bimekizumab shows significant potential for treating ankylosing spondylitis (AS) - Oral presentation on CIMZIA® (certolizumab pegol) pregnancy outcomes shows no increased risk of major congenital malformations compared to the general population nor an ...
mehrIMI-PainCare: Public-private partnership tackles major challenges in the care of pain patients
Aachen (ots) - To improve the care of patients with acute or chronic pain, a consortium from academia, small and medium-sized enterprises (SMEs), pain societies, patient organizations and pharmaceutical industry launched the research project "IMI-PainCare - Improving the care of patients suffering from acute or ...
mehrMerck Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO 2018
Darmstadt, Germany (ots/PRNewswire) - ASCO Abstract # M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566, TPS3130; Tepotinib (c-Met kinase inhibitor): 9082, 9016; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814 (DNA-PK): 2518 Not intended for UK- or US-based media - M7824 is an investigational immunotherapy that is designed to bring together ...
mehr
Hitachi Medical Systems Europe Holding AG
Hitachi Medical Systems Europe wins the contract to supply 6 ultrasound systems in the UK helping to improve prostate cancer diagnosis ...
Zug, Switzerland (ots) - Hitachi Medical Systems Europe wins the contract to supply 6 ultrasound systems in the UK helping to improve prostate cancer diagnosis as part of the innovative RAPID programme at three major hospitals across South West London The new RAPID (Rapid Assessment Prostate Imaging and Diagnosis) ...
mehrTwo Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab)
Chicago (ots/PRNewswire) - Not intended for US, Canada and UK-based media - Two-year follow-up data on meaningful durable response, overall survival (OS) and progression-free survival (PFS) to be presented in patients with metastatic Merkel cell carcinoma (mMCC), a rare and aggressive type of skin cancer Merck and ...
mehrMerck Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018
Darmstadt, Germany (ots/PRNewswire) - ASCO Abstract # Tepotinib (c-Met kinase inhibitor): 9082, 9016; M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814 (DNA-PK): 2518 Not intended for UK- or US-based media - Data from an ongoing Phase II tepotinib study show anti-tumor clinical activity in ...
mehrTakeda Pharmaceutical Company Limited
Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFalpha-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease
Osaka, Japan (ots/PRNewswire) - Takeda demonstrates leadership in GI by featuring new U.S. VICTORY Consortium data among its 24 sponsored Entyvio abstracts presented at the Digestive Disease Week (DDW) 2018 meeting Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today announced a new analysis of ...
mehrGalderma Global Study Reveals True Burden of Rosacea and Encourages Healthcare Professionals to Look 'Beyond the visible'
Lausanne, Switzerland (ots/PRNewswire) - Galderma today released the findings of a global survey highlighting the need for dermatologists and doctors to proactively open a dialogue with patients about the true burden of rosacea and ways in which they can work together to achieve 'clear' (IGA 0) skin*. In the form of ...
mehrWorld MS Day 2018: Call for Greater Curiosity to Drive Understanding of the Disease and Future Innovation
Darmstadt, Germany (ots/PRNewswire) - - Launch of #MSInsideOut campaign, aimed at providing a deeper understanding of multiple sclerosis (MS) - Donation to the MS International Federation (MSIF)* of up to EUR20,000 - Shift.ms to Executive Produce a documentary to highlight stories and unique perspectives within the ...
mehr
European Society for Medical Oncology (ESMO)
ESMO emphasises importance of cancer on global health agenda at WHA
mehrReal-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda®
Vienna (ots/PRNewswire) - People treated with Saxenda® (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European Congress on Obesity (ECO 2018) in Vienna, Austria and the 23rd Annual International Meeting of the ...
mehrUCB Joins with ILAE and IBE to Encourage World Health Assembly Members to Continue Recognition of Epilepsy as Global Health Priority
Brussels and Geneva (ots/PRNewswire) - - Significant gaps in epilepsy management, awareness, and effective treatment access continue around the world - Groups are launching a call to action for public and private engagement to join the fight against Epilepsy through a sustained commitment towards the Resolution on ...
mehrHead-to-Head Trial Shows Refixia® Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein
Glasgow, Scotland (ots/PRNewswire) - Adults with haemophilia B who received a single dose Refixia® (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed a longer half-life for ...
mehrNovoEight® Maintains Potency When Stored at 40ºC Offering People With Haemophilia A Increased Flexibility in Their Daily Lives
Glasgow, Scotland (ots/PRNewswire) - A new long term stability study has shown that haemophilia A treatment NovoEight® (turoctocog alfa) remains potent after three months exposure to temperatures of 40ºC.[1] The results were presented today at the WFH 2018 World Congress in Glasgow, UK. Treatment storage issues, ...
mehrLIXIANA® (edoxaban) Shows Reduced Rate of a Variety of Types of Intracranial Haemorrhage Compared to Warfarin in New Sub-analysis Presented at the European Stroke Organisation Conference 2018
Munich (ots/PRNewswire) - - Sub-analysis presented from ENGAGE AF-TIMI 48, the longest single comparative global trial of a non-vitamin K oral anticoagulant (NOAC) in patients with non-valvular atrial fibrillation (NVAF) to date - Results showed a reduction in both spontaneous and traumatic intracranial haemorrhage ...
mehr
Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)
Novato, California, Tokyo and London (ots/PRNewswire) - Substantial Healing of Rickets Observed in 72% of Patients Treated with Crysvita Compared to 6% of Patients Receiving Conventional Therapy at 40 Weeks Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel ...
mehrMerck Data at ASCO 2018 to Showcase Progress and Further Optionality of Oncology Pipeline
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media ASCO Abstract # ERBITUX® (cetuximab): 3521, 3534, e15711; avelumab: 9507, 9537, 9090, 9008, 8563, 3057, 4544, e21531, e13603, e18932, e21623, e21620, e21544; tepotinib (c-Met kinase inhibitor): 9082, 9016; M6620 (ATR inhibitor): 2549, e21048; M3814 (DNA-PK): 2518 M7824 (TGF-ß ...
mehrSequana Medical announces inclusion of alfapump® in EASL Clinical Practice Guidelines and presentation of study demonstrating physical component of QOL is predictor of mortality in refractory ascites
Zurich (ots) - Sequana Medical AG ("Sequana Medical"), a commercial stage medical device company and an innovator in the management of liver disease & malignant ascites, announces two important developments at the recent EASL (European Association for the Study of the Liver) International Liver Congress 2018. First, ...
mehrBioLamina and Novo Nordisk Partner to Advance Stem Cell Based Therapies for Three Common Medical Conditions
Stockholm (ots/PRNewswire) - BioLamina and collaborators have partnered with Novo Nordisk A/S (Novo Nordisk), a Danish multinational pharmaceutical company, allowing Novo Nordisk to develop novel stem cell based therapies based on Biolaminins, human recombinant laminin cell culture matrices, developed and produced ...
mehrAccuray Unveils New Company Website Reflecting Industry-Leading Patient-First Cancer Treatment Innovation and Care
Sunnyvale, California (ots/PRNewswire) - Accuray Incorporated (Nasdaq: ARAY) announced today the unveiling of a new corporate website that reflects the company's evolution and leadership in patient-first cancer treatment innovations. The fully redesigned, modern site puts critical disease and treatment information ...
mehrUCB Announces BRIVIACT® (Brivaracetam) now Approved by FDA to Treat Partial-onset (Focal) Seizures in Pediatric Epilepsy Patients
Atlanta and Brussels (ots/PRNewswire) - - BRIVIACT® (brivaracetam) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures - Approval provides pediatric epilepsy patients a treatment option which can be initiated at a therapeutic ...
mehr
SciBite and ChemAxon to Deliver an Integrated Solution for Biology and Chemistry Research
Cambridge, England (ots/PRNewswire) - SciBite (https://www.scibite.com/), the award-winning semantic analytics company, today announced a strategic partnership with ChemAxon (https://chemaxon.com/), the leading cheminformatics company, enabling Pharmaceutical companies to capitalise on unlocking the wealth of R&D data that is at their disposal. (Logo: ...
mehrMavenclad (Cladribine Tablets) Data in Multiple Sclerosis Journal Show an Even Greater Treatment Effect in Patients With Highly Active Multiple Sclerosis
Darmstadt, Germany (ots/PRNewswire) - - Post-hoc analysis from the 2-year CLARITY study demonstrated that Mavenclad reduced the risk of 6-month EDSS progression by 47% vs placebo - Patients with highly active multiple sclerosis had an even greater treatment effect, reducing the risk by 82% vs placebo Merck, a ...
mehrBioLamina Launches a Cell Therapy Grade Stem Cell Culture Matrix, Biolaminin 521 CTG, Bridging Discovery and Clinical Cell Therapy
Stockholm (ots/PRNewswire) - BioLamina (http://www.biolamina.com) (Stockholm) is currently undergoing an exciting phase entering the growing cell and gene therapy reagents industry. In order to meet the growing demand for documentation and traceability required for the manufacture of cells for therapy, BioLamina has ...
mehrUCB Announces Positive CHMP Opinion for CIMZIA® (certolizumab pegol) in Patients with Moderate-to-Severe Plaque Psoriasis
Brussels (ots/PRNewswire) - Strictly not for UK/Irish media - CIMZIA® (certolizumab pegol) Phase 3 psoriasis data demonstrated significant and clinically meaningful improvements in biologic-naïve and previously treated patients, with clinical benefit maintained up to one year[1] - This milestone represents UCB's ...
mehrConstance Therapeutics and Kanabo Research
Israel-Based Medical Cannabis Solutions Provider, Kanabo Research, has Signed an Agreement With Constance Therapeutics From the US
Tel Aviv, Israel (ots/PRNewswire) - Israeli startup Kanabo Research (http://www.kanaboresearch.com/), which develops clinical solutions for extraction and vaporization of medical cannabis, announces it is entering an agreement with Constance Therapeutics, a US-based medical cannabis extraction company. (Photo: ...
mehrFreenome and Biognosys announce collaboration to improve early-cancer detection and treatment
South San Francisco, California, USA and Schlieren, Switzerland (ots) - AI genomics company Freenome announces partnership with leading proteomics company Biognosys to enhance its broad-signal approach to early-cancer detection and precision oncology. By decoding cell-free (cf) biomarker patterns of once unthinkable ...
mehr
Vorherige22232425262728293031Nächste